This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Skipper, P. L. Articles by Yu, M. C. Search for Related Content PubMed PubMed Citation Articles by Skipper, P. L. Articles by Yu, M. C.

Nonsmoking-related Arylamine Exposure and Bladder Cancer Risk¹

Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 [P. L. S., S. R. T.], and University of Southern California/Norris Comprehensive Cancer Center, Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California [R. K. R., M. C. Y.]

Roughly one-half of bladder cancer incidence in the United States can be attributed to known causes, mainly cigarette smoking, and it has been hypothesized that the aromatic amines in tobacco smoke are important etiological agents. Nonsmokers are also exposed, through unknown sources, to many of the same carcinogenic aromatic amines that are present in cigarette smoke. Previous epidemiological studies have not tested whether either of these aromatic amine exposures are associated with cancer risk. We conducted a population-based case-control study in Los Angeles County, California, involving 761 case patients with bladder cancer and 770 individually matched control subjects. In-person interviews provided information on tobacco smoking and other potential risk factors. Quantitative analysis of hemoglobin adducts of 4- and 3-aminobiphenyl (ABP) was used to assess aromatic amine exposure. Adducts of both aminobiphenyls were significantly higher in cases than in controls, independent of cigarette smoking at the time of blood collection and lifetime smoking history. Adjustment for other risk factors as well as for metabolic differences did not materially alter the associations. Our findings strengthen the connection between exposure to aromatic amines in tobacco smoke and cigarette smoking-related bladder cancer and suggest that environmental exposure to arylamines may account for a significant proportion of nonsmoking-related bladder cancer in the general population.

This article has been cited by other articles:

				X. Jiang, J.-M. Yuan, P. L. Skipper, S. R. Tannenbaum, and M. C. Yu Environmental Tobacco Smoke and Bladder Cancer Risk in Never Smokers of Los Angeles County Cancer Res., August 1, 2007; 67(15): 7540 - 7545. [Abstract] [Full Text] [PDF]

				B. Zayas, S. W. Stillwell, J. S. Wishnok, L. J. Trudel, P. Skipper, M. C. Yu, S. R. Tannenbaum, and G. N. Wogan Detection and quantification of 4-ABP adducts in DNA from bladder cancer patients Carcinogenesis, February 1, 2007; 28(2): 342 - 349. [Abstract] [Full Text] [PDF]

				L. Airoldi, P. Vineis, A. Colombi, L. Olgiati, C. Dell'Osta, R. Fanelli, L. Manzi, F. Veglia, H. Autrup, A. Dunning, et al. 4-Aminobiphenyl-Hemoglobin Adducts and Risk of Smoking-Related Disease in Never Smokers and Former Smokers in the European Prospective Investigation into Cancer and Nutrition Prospective Study Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2118 - 2124. [Abstract] [Full Text] [PDF]

				H. Wallerand, A. A. Bakkar, S. G. D. de Medina, J.-C. Pairon, Y.-C. Yang, D. Vordos, H. Bittard, S. Fauconnet, J.-C. Kouyoumdjian, M.-C. Jaurand, et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens Carcinogenesis, January 1, 2005; 26(1): 177 - 184. [Abstract] [Full Text] [PDF]

				J. Gan, P. L. Skipper, M. Gago-Dominguez, K. Arakawa, R. K. Ross, M. C. Yu, and S. R. Tannenbaum Alkylaniline-Hemoglobin Adducts and Risk of Non-Smoking-Related Bladder Cancer J Natl Cancer Inst, October 6, 2004; 96(19): 1425 - 1431. [Abstract] [Full Text] [PDF]

				V. K. Cortessis, K. Siegmund, S. Xue, R. K. Ross, and M. C. Yu A case-control study of cyclin D1 CCND1 870A->G polymorphism and bladder cancer Carcinogenesis, October 1, 2003; 24(10): 1645 - 1650. [Abstract] [Full Text] [PDF]